$STE (Steris Plc)

$STE {{ '2015-12-22T12:22:42+0000' | timeago}} • Announcement

Healthcare services provider $STE said that it expects combined revenue growth of 21-22% for FY16 compared to FY15. Adjusted diluted EPS is expected to be in the range of $3.48-3.55 and adjusted effective tax rate of approx. 27.5%. Free cash flow to be approx. $155MM including acquisition-related cost of $45MM & CapEx of approx. $135MM.

$RMD {{ '2018-01-22T22:00:14+0000' | timeago}} • Announcement

Hurt by one-time charges related to the US tax reform, $RMD reported 88% decline in 2Q18 earnings to $9.5MM, or 7 cents per share. Excluding these charges, net income rose 37% to $1 during the quarter. Meanwhile, revenue jumped 13% to $601.3MM.

$RMD {{ '2018-01-22T21:48:59+0000' | timeago}} • Infographic

$RMD ResMed Inc. Earnings AlphaGraphic: Q2 2018 Highlights

$CELG {{ '2018-01-22T13:26:32+0000' | timeago}} • Announcement

Last week's rumor becomes reality. $CELG to acquire its strategic partner $JUNO for $9Bil. Juno Therapeutics, which had already skyrocketed nearly 50% in the last week, has increased more than 25% today in pre-market from Jan. 19th closing price of $67.81. Celgene expects that this deal will help it to boost the revenue generation beyond 2020.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$XRAY {{ '2018-01-17T20:31:22+0000' | timeago}} • Announcement

$XRAY's BoD has appointed Donald M. Casey Jr. as CEO and board member of the company, effective Feb. 12, 2018. Casey succeeds Mark A. Thierer, who served as Interim CEO since Sept. 28, 2017.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$KAMN {{ '2018-01-16T17:22:14+0000' | timeago}} • Announcement

$KAMN said its Aerospace segment received a contract modification in excess of $17MM for the procurement of Joint Programmable Fuzes. The award is an additional order under Option 13 of the JPF contract with the US Air Force. The modification increases the total value of Option 13 to more than $102MM, all of which was in backlog at Dec. 31, 2017.

$KAMN {{ '2018-01-10T19:21:07+0000' | timeago}} • Announcement

$KAMN announced that Rebecca F. Stath has been appointed to serve as Assistant Vice President, SEC Compliance and External Reporting, reporting to John J. Tedone, Vice President, Finance and Chief Accounting Officer.

$KAMN {{ '2018-01-10T19:16:01+0000' | timeago}} • Announcement

$KAMN announced that Amanda N. Balboni has been appointed to serve as Assistant Vice President, Internal Audit. Ms. Balboni has previously worked at Coburn Technologies, Stanley Black & Decker and PricewaterhouseCoopers.

$PII {{ '2018-01-09T19:13:23+0000' | timeago}} • Announcement

$PII named Lucy Clark Dougherty as its SVP, General Counsel, Compliance Officer and Corporate Secretary, reporting to Chairman and CEO Scott Wine effective Jan. 29, 2018. Dougherty will also serve as president of the Polaris Foundation.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$IDXX {{ '2018-01-05T12:52:03+0000' | timeago}} • Announcement

$IDXX expects the recently passed Tax Cuts and Jobs Act to benefit the company by reducing its recurring effective tax rate beginning in 2018, by approx 750-850 bps. It also estimates that the enactment of the tax legislation will result in a one-time reduction of about $35-45MM in earnings for 4Q17 and FY17.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
SRCL (Stericycle, Inc.)
Wednesday, November 8 2017 - 10:01pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
CYH (Community Health Systems, Inc.)
Thursday, November 2 2017 - 3:00pm
KTWO (K2M Group Holdings, Inc.)
Wednesday, November 1 2017 - 9:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
AET (Aetna Inc.)
Tuesday, October 31 2017 - 12:30pm
KAMN (Kaman Corporation)
Friday, October 27 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like